Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

Lowkeyoptions Aug. 15 at 10:44 AM

$TENX watching bashers go bullish here is funny. Those 13g filings all dropped ah and i feel that was on purpose. Count up the millions held now plus company shares held. $CAPR $RGC $DRUG $PFE

1 · Reply

GordoHLYK13 Aug. 15 at 7:58 AM

$IGC That’s a 6-year-old, fully resolved SEC matter—not a current investigation or operational issue. The business has completely transformed from its 2020 infrastructure/cannabis roots into IGC Pharma, a clinical-stage biotech focused on Alzheimer’s. Today, the story is Phase 2 CALMA, IGC-AD1, and the upcoming Q4 2026 data—not recycled 2020 paperwork. Bringing up ancient, settled filings to create fresh fear is noise. Watch the clinical data, not the archives. $IGC 🚀📈 $PFE $ABBV $MRNA Shorts are digging deep for old narratives—looks like fear is building ahead of IGC’s Phase 2 results. The closer we get to the data, the louder the noise gets. $IGC 🚀📈

1 · Reply

Trade111222 Aug. 15 at 1:30 AM

$PFE back to 25.5 next week or below

0 · Reply

Lowkeyoptions Aug. 14 at 11:14 PM

$TENX 4 new 13G just dropped nothing left for retail 1.6 million 2.9 million 1.4 million 3.4 million 9 million 1.6 million Do the maths on this insider load Wtf!! 118 million in cash $CAPR $RGC $DRUG $PFE

1 · Reply

Bob67_ Aug. 14 at 10:50 PM

$ELTP $GME $META $PFE Nope.

0 · Reply

JBS_84 Aug. 14 at 9:37 PM

$PFE I expect sideways consolidation for a bit

0 · Reply

Micheal_Pothead Aug. 14 at 9:04 PM

$PFE just a PSA, we crossed the 200 week moving average last week and held it this week

1 · Reply

Micheal_Pothead Aug. 14 at 7:45 PM

$PFE shorts are mad

0 · Reply

Micheal_Pothead Aug. 14 at 7:14 PM

$PFE 27.01 close would confirm 30 imo

2 · Reply

BarkingPuppy Aug. 14 at 7:05 PM

$ELTP $DJT $GME $PFE $JNJ The Rumors in the Bio-tech world are going crazy. Who is going to Grab ELTP in America Before a Foreign Company Buys them???? I would like to keep it in American Hands, I think their ART technology is far to great and powerful to let a none US company acquire this There is no official corporate announcement or confirmed agreement that Elite Pharmaceuticals (ELTP) is being bought by a foreign buyer. Online retail investor communitie have heavily speculated about a potential company buyout—including theories involving international or foreign acquirers motivated by manufacturing capacities or tariff strategies. However, these claims remain unverified market speculation and rumor rather than official business operations. The company's management has previously discussed a sale or buyout as a strategic option to maximize shareholder value or address listing requirements, but no foreign acquisition deal has been finalized or announced.

0 · Reply

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

PFE

Aug 14, 2026, 11:46 AM EDT - 19 hours ago

Closed Pfizer biopharma facility in Everett gets a new lease on life

PFE

Aug 14, 2026, 11:11 AM EDT - 20 hours ago

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

PFE

Aug 14, 2026, 1:00 AM EDT - 1 day ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

PFE VALN

Aug 14, 2026, 1:00 AM EDT - 1 day ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

PFE VALN

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 7:24 AM EDT - 11 days ago

Pfizer Post Loss on Higher Revenue

PFE

Aug 4, 2026, 7:13 AM EDT - 11 days ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

PFE

Aug 4, 2026, 7:12 AM EDT - 11 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX PFE

Aug 4, 2026, 6:52 AM EDT - 11 days ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

PFE

Aug 4, 2026, 6:45 AM EDT - 11 days ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

PFE

Aug 3, 2026, 8:10 AM EDT - 11 days ago

5 Things to Know Before the Stock Market Opens on Monday

AMD AZN BMY CAT CVS DASH DIS

Jul 30, 2026, 7:48 AM EDT - 15 days ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

PFE

Jul 30, 2026, 6:45 AM EDT - 16 days ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

PFE

Jul 29, 2026, 4:30 PM EDT - 16 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX PFE

Jul 22, 2026, 4:48 PM EDT - 23 days ago

Pfizer's prostate cancer drug combination gets US FDA priority review

PFE

Jul 22, 2026, 4:30 PM EDT - 23 days ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

PFE

Jul 21, 2026, 7:10 PM EDT - 24 days ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY PFE

Jul 16, 2026, 1:39 PM EDT - 4 weeks ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

PFE

Jul 10, 2026, 11:23 AM EDT - 5 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

PFE

Jul 6, 2026, 10:00 AM EDT - 5 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

PFE

Jun 29, 2026, 4:43 PM EDT - 6 weeks ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Jun 29, 2026, 1:20 AM EDT - 6 weeks ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

PFE

Jun 24, 2026, 3:52 PM EDT - 7 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend

PFE

Jun 24, 2026, 2:10 PM EDT - 7 weeks ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

PFE

Jun 24, 2026, 10:51 AM EDT - 7 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit

PFE

Jun 23, 2026, 12:10 PM EDT - 7 weeks ago

China outpacing Europe in drug innovation and development, Pfizer executive says

PFE

Jun 23, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

PFE

Jun 22, 2026, 4:43 PM EDT - 7 weeks ago

Pfizer's experimental drug misses main goal of lung cancer trial

PFE

Jun 22, 2026, 4:30 PM EDT - 7 weeks ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

PFE

Jun 22, 2026, 2:32 PM EDT - 7 weeks ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG PFE

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August

PFE

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition

PFE

Jun 10, 2026, 7:56 AM EDT - 2 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

PFE

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS PFE VZ

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO PFE

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK PFE RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

PFE

Jun 8, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

PFE

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

PFE

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

PFE

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

PFE

Jun 4, 2026, 6:40 AM EDT - 2 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY PFE

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

PFE

May 31, 2026, 8:00 AM EDT - 2 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

PFE

May 30, 2026, 8:00 AM EDT - 2 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

PFE

May 29, 2026, 8:00 AM EDT - 2 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

PFE

May 28, 2026, 11:10 PM EDT - 2 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

PFE

May 28, 2026, 7:19 PM EDT - 2 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

PFE

May 28, 2026, 7:00 PM EDT - 2 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

PFE

Lowkeyoptions Aug. 15 at 10:44 AM

$TENX watching bashers go bullish here is funny. Those 13g filings all dropped ah and i feel that was on purpose. Count up the millions held now plus company shares held. $CAPR $RGC $DRUG $PFE

1 · Reply

GordoHLYK13 Aug. 15 at 7:58 AM

1 · Reply

Trade111222 Aug. 15 at 1:30 AM

$PFE back to 25.5 next week or below

0 · Reply

Lowkeyoptions Aug. 14 at 11:14 PM

1 · Reply

Bob67_ Aug. 14 at 10:50 PM

$ELTP $GME $META $PFE Nope.

0 · Reply

JBS_84 Aug. 14 at 9:37 PM

$PFE I expect sideways consolidation for a bit

0 · Reply

Micheal_Pothead Aug. 14 at 9:04 PM

$PFE just a PSA, we crossed the 200 week moving average last week and held it this week

1 · Reply

Micheal_Pothead Aug. 14 at 7:45 PM

$PFE shorts are mad

0 · Reply

Micheal_Pothead Aug. 14 at 7:14 PM

$PFE 27.01 close would confirm 30 imo

2 · Reply

BarkingPuppy Aug. 14 at 7:05 PM

0 · Reply

GordoHLYK13 Aug. 14 at 6:34 PM

$IGC Pay attention—you're about to see a late-session surge right before the closing bell. Supporting Factors for Late-Day Moves Institutional MOC Orders: Market-On-Close (MOC) imbalance data is released in the final 20–30 minutes, frequently driving sharp institutional volume and rapid price jumps into the bell. Intraday Short Covering: Day traders and short sellers closing out intraday positions before the bell forces quick buy-side pressure to prevent overnight gap risk. Options Gamma Hedging: Market makers rebalancing delta-neutral positions toward the end of the session can accelerate momentum in the underlying asset if key strike prices are broken. Power Hour Volume: Trading volume routinely spikes during the final hour as funds align capital allocations before liquidity dries up post-market. $UMAC $PFE $MRNA

0 · Reply

INEEDMONEY87 Aug. 14 at 5:46 PM

$PFE i love a good undercut and rally

0 · Reply

EmbraceVolatility Aug. 14 at 5:29 PM

$PFE 1 more dollar until 52 week high (divvy adjusted). Then we see if we can breakout. $30 anyone?

1 · Reply

GoforProMIS Aug. 14 at 5:20 PM

$PMN Guggenheim raised PT to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $PFE $JNJ $BMY

0 · Reply

CapitalMonk Aug. 14 at 4:56 PM

$PFE Price: $26.76 (-0.13%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.09% RSI: 74.2 | Momentum: Moderate Volume: -72.3% vs avg Volatility: 1.18% Support: $24.23 | Resistance: $27.20 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

BarkingPuppy Aug. 14 at 4:24 PM

$ELTP $PFE $GME $META GREAT Call today. They Mentioned Trump ( in a good way ) One of the most talked-about rumors circulating is a potential share buyback program. If this comes to fruition, it would be a powerful signal of confidence from the company’s leadership, aiming to increase shareholder value by reducing outstanding shares and demonstrating belief in the company’s future prospects. Interestingly, for the first time ever, there was no mention of SequestOx during the call. Historically, SequestOx has been a frequent topic, so its absence is notable. In the world of corporate communications, silence on a previously prominent subject often suggests positive developments—nine times out of ten, it means there’s good news brewing behind the scenes. ELTP stock is now in play after this call. ( Roaring Kitty ? )

3 · Reply

nimii Aug. 14 at 4:16 PM

$PFE ☹️

0 · Reply

TraderDaKing Aug. 14 at 4:09 PM

$ELTP $PFE $BAC $SPCX Call Conference was Great. Up-listing and Partnership confirmed and in the works. Thank God. Watch the Big Share buyback now through next year. Should drive it to 1.20 range.

1 · Reply

StocktwitsNews Aug. 14 at 3:54 PM

Why Did VALN Stock Surge 24% Today? $VALN $PFE https://stocktwits.com/news/equity/markets/why-did-valn-stock-surge-24-today/cZotV7rRJ0j

0 · Reply

TraderDaKing Aug. 14 at 3:28 PM

$JNJ $PFE $LLY $MRNA I know you are listening and buying after the new during the call. Elite Pharma. Welcome to the Big Times.

0 · Reply

Samishere Aug. 14 at 3:27 PM

$BNTX $GSK $MRNA $PFE

1 · Reply

TraderDaKing Aug. 14 at 3:23 PM

$ELTP $GME $DJT $PFE YOU DO NOT WANT TO MISS THIS CONFERENCE CALL. ELTP STOCK WILL RUN AFTER THIS CALL. Date: August 14, 2026 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840

1 · Reply

Market Cap	152.75B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.63
Forward PE	8.84
Profit Margin	12.42%
Debt to Equity Ratio	0.74

Volume	23,174,100
Avg Vol	44,246,344
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	84%
Beta	0.34
Analysts	Sell
Price Target	$28.60